A recent study reported similar efficacies of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) in patients with EGFR mutation‐positive adenocarcinoma in terms of ORR, PFS, and OS, irrespective of the timing of treatment 19. Here, EGFR is linked to adenocarcinoma.